Navigation Links
Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology

WEST LAFAYETTE, Ind., Oct. 4, 2011 /PRNewswire/ -- Kylin Therapeutics, Inc., a leading second-generation RNAi company, announced today that it has received a notice of allowance from United States Patent and Trademark Office (USPTO) for its second U.S. patent application. This newly allowed patent broadly covers new therapeutic RNA technology, as well as expanded areas on Kylin's proprietary nanoparticle technology platform, "pRNA" ("packaging RNA"). This new intellectual property covers multi-valent RNA structures broadly encompassing: tissue targeting, aptamer binding, receptor-mediated endocytosis, and RNA interference. "We continue to be gratified that the USPTO recognizes pRNA as an entirely unique platform in the crowded RNAi intellectual property space," said J. Eric Davis, J.D., President and Chief Executive Officer of Kylin Therapeutics, Inc.

Upon issuance, this will be Kylin's second U.S. patent. Along with its other issued and granted pRNA patents in Europe, Australia, and the United States, Kylin believes that this seminal patent family represents rare "new ground" in the field of RNAi and the delivery of therapeutic RNA. Kylin has a total of five patent families, with several other applications in the pipeline. "The unexpected, pharmacologically robust nature of the pRNA platform continues to allow Kylin to claim more ground in areas such as RNAi and tissue-specific targeting," said Homer Pearce, Ph.D., Director and Chairman of Kylin's Scientific Advisory Board.

Kylin's pRNA intellectual property estate is based upon the innovative discoveries of Peixuan Guo, Ph.D., and others at Kylin, on the design and creation of novel, therapeutically relevant RNA molecules. These molecules can be engineered as RNA multiplexes that function as RNAi-inducing DICER substrates and tissue-targeting modalities, and they can be used systemically and discretely without additional delivery components. Kylin has continued and expanded upon the work of Dr. Guo, demonstrating the improved pharmacokinetics of pRNA molecules in several relevant in vivo model systems, primarily in cancer.

"The pRNA patents are a result of Kylin's and Dr. Guo's visionary efforts to borrow from nature and create novel, therapeutically superior RNA molecules," said Davis. "We continue to believe this is an entirely new intellectual property landscape in the field of RNA-based therapeutics, one that is distinct and protectable from other patents in the RNAi and antisense fields."

Following a Notice of Allowance, the process resulting in final issuance of a patent involves a number of administrative steps that are typically completed in a few months.

About Kylin Therapeutics

Kylin Therapeutics, Inc., a second-generation RNAi company, employs a revolutionary RNA nanoparticle technology platform called "pRNA" to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. This visionary platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies.

Contact: Eric Davis, Kylin Therapeutics, 919-386-9694,,

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

SOURCE Kylin Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Skyline Diagnostics Establishes Research Collaboration With Janssen
2. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
4. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
5. Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
6. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
7. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
8. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
9. FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech
10. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
11. PTC Therapeutics and Genzyme Announce Restructuring of Collaboration
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... on what they believe could be a new and helpful biomarker for malignant ... Click here to read it now. , Biomarkers are components in ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
Breaking Biology News(10 mins):